Common variable immunodeficiency confirmation flow panel
Common variable immunodeficiency confirmation flow panel-994
Common variable immunodeficiency confirmation flow panel
994
LAB994
MSO
- Screening for common variable immunodeficiency (CVID)
- Identifying defects in TACI and BAFF-R in patients presenting with clinical symptoms and other laboratory features consistent with CVID
- Evaluating B cell immune competence by assessing expression of BAFF-R and TACI proteins
- Assessing BAFF-R and TACI protein expression and frequency of B cells bearing these receptors. TNFRSF13C (BAFF-R) and TNFRSF13B (TACI) gene mutations have been described in a small subset of patients with humoral immunodeficiencies classified as CVID. The majority of TNFRSF13B mutations preserve TACI protein expression and require genetic testing to identify pathogenic or potentially pathogenic mutations/variants.
EDTA whole blood
>14 years: 10 mL
≤14 years: 4.0 mL
≤14 years: 4.0 mL
>14 years: 5 mL
≤14 years: 3.0 mL
≤14 years: 3.0 mL
- Collect samples Mo - Th only
- Immediately following collection, mix sample thoroughly by gently inverting 8 - 10, times to prevent clotting
Lavender (EDTA), 4mL tube(s)
Refrigerated - 48 hours
Specimens are required to be received at the performing laboratory by 4pm, Mo - Fri. No weekend processing.
Mayo Clinic Laboratories (CVID): R-NX
Mo - Fr
3 - 4 days
Fluorescent flow cytometry
%CD19+TACI+: > 3.4%
%CD19+BAFF-R+: >90.2%
%CD19+BAFF-R+: >90.2%
TNFRSF13C (BAFF-R) and TNFRSF13B (TACI) gene mutations have been described in a small subset of patients with humoral immunodeficiencies classified as CVID. The majority of TNFRSF13B mutations preserve TACI protein expression and require genetic testing to identify pathogenic or potentially pathogenic mutations/variants.
88184
88185 x 2
88185 x 2
07/15/2019
07/15/2019
01/12/2024